SCHEMBL10177301

SCHEMBL10177301

Nc1cccc(-c2cnc3cc(-c4cnn(C5CCN(C(=O)C6(N)CC6)CC5)c4)cnn23)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAP3K7 O43318 5/20 0.46
TAB1 Q15750 5/20 0.46
FGFR3 P22607 3/20 0.44
FGFR1 P11362 1/20 0.44
KDR P35968 3/20 0.42
FYN P06241 2/20 0.40
MET P08581 6/20 0.39
MAP4K3 Q8IVH8 1/20 0.39
DYRK3 O43781 1/20 0.39
CCNT1 O60563 1/20 0.39
CCNA2 P20248 1/20 0.39
CDK2 P24941 1/20 0.39
CDK9 P50750 1/20 0.39
CDK5 Q00535 1/20 0.39
DYRK1A Q13627 1/20 0.39
CDK5R1 Q15078 1/20 0.39
DYRK2 Q92630 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
PIK3CD O00329 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10176578 0.93 MAP3K7 (0.46) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10176117 0.92 MAP3K7 (0.46) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10177430 0.87 MAP3K7 (0.46) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10177429 0.85 FGFR3 (0.47) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10176243 0.84 KDR (0.46) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10176246 0.84 FGFR3 (0.51) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10176110 0.84 MET (0.54) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10176389 0.83 FYN (0.45) MAP3K7TAB1FGFR3FGFR1KDR
SCHEMBL10177281 0.81 MAP4K3 (0.52) METMAP4K3
SCHEMBL10176147 0.81 MAP3K7 (0.43) MAP3K7TAB1FGFR3FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 MAP3K7 717/4885TAB1 490/4885FGFR3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.